Date and Time: February 17 at 4 PM GMT / 11 AM EST / 8 AM PST
Biomarkers have become an essential part of the drug discovery and development process. A biomarker-driven approach to developing targeted therapies and patient selection strategies has the potential to increase success in the drug development process, decrease costs, and ultimately improve patient outcomes.
But what about imaging biomarkers? Usually obtained from PET, MRI, and CT scans, they comprise measurements of structural and metabolic features of the body that over time are used to assess disease progression and response to treatment. Imaging biomarkers are an ideal method to draw evidence from retrospective data and can be used both as inclusion criteria—to select relevant cohorts of patients and output data—to quantify responses to treatments.
- How to use imaging in early clinical trials for an increased confidence in the target and in the new drug discovery?
- From the investigator perspective, how to best combine standard imaging and advanced, personalized phenotypic endpoints in clinical trials?
- Radiomics, ML and AI, digital patient, synthetic control arms .. : Where the future of imaging is?
- How to massively access real world quality data to create data lake and to develop new imaging markers?
- Jerome Windsor, PharmD, MBA (Moderator), Advisor, Boston Digital Bio Consulting
- Karine Seymour, MBA, CIO, Medexprim
- Tim McCarthy, PhD, MBA, VP and Digital Medicine Head, Pfizer
- Prof. Laure Fournier, Academic Radiologist, Hôpitaux de Paris
- Angel Alberich-Bayarri, PhD, CEO, Quibim